Long-term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single-center retrospective study.
Yu ZhouYan QinXiaohui HePeng LiuJianliang YangLiqiang ZhouShengyu ZhouLin GuiSheng YangChanggong ZhangYuan-Kai ShiPublished in: Asia-Pacific journal of clinical oncology (2020)
This study showed that rituximab maintenance after chemoimmunotherapy induction can prolong both PFS and OS in patients with advanced-stage FL, and FLIPI2 is a promising prognostic model.